Global Soft Tissue Sarcoma Treatment Market Size/Share 2023 Estimated to Reach USD 3,704.27 Million By 2032, at 10.7% CAGR: Analysis by Polaris Market Research


[115+ Pages Research Study] According to Polaris Market Research, the global soft tissue sarcoma treatment market Size & share was valued at USD 1,341.59 Million in 2022 and is predicted to increase at a CAGR of 10.7%, to reach USD 3,704.27 Million By 2032. Increasing prevalence of this type of cancer in the region, as well as the availability of advanced treatments. Some of the key players covered are Bristol-Myers Squibb, Merck & Co., Eli Lilly and Company, Novartis AG, Pfizer Inc., GlaxoSmithKline plc and others.

New York, NY, March 20, 2023 (GLOBE NEWSWIRE) — Polaris Market Research has published a new research report titled “Soft Tissue Sarcoma Treatment Market Share, Size, Trends, Analysis, Industry Report by Treatment, By Disease, By Distribution Channel, By End User and Forecast, 2023 – 2032” in its research database.

“According to the latest research study, the global soft tissue sarcoma treatment market size/share is anticipated to be valued at approximately USD 1,341.59 Million in 2022 and is projected to hit a revenue of around USD 3,704.27 Million By 2032, at a CAGR of around 10.7% between 2023 and 2032.”


What is Soft Tissue Sarcoma Treatment? What is the Expected Size/Share of the Soft Tissue Sarcoma Treatment Market?

  • Report Overview

Sift tissue sarcoma is an infrequent kind of cancer that commences in the tissues that secure, reinforce and encircle other body formations. The rapidly rising demand for the soft tissue sarcoma treatment market can be attributed to the increase in surgeries that involve detaching cancer and some healthy tissue encircling it. When soft tissue sarcoma impacts the arms and legs, radiation and chemotherapy might be contemplated to reduce the tumor to circumvent amputation.

The market’s growth is extensively driven by factors such as contemporary product instigation, growing acceptance of new therapeutics, and increasing target population. The instigation of targeted therapy has transformed the treatment paradigm for sarcoma. Targeted therapies and imminent developments will persist in playing an integral role in the market’s growth throughout the forecast period.

Request Sample Copy of Soft Tissue Sarcoma Treatment Market Research Report @

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)

Our Sample Report May Includes:

  • 2032 Updated Report Introduction, Overview, and In-depth industry analysis.
  • 115+ Pages Research Report (Inclusion of Updated Research).
  • Provide Chapter-wise guidance on Requests.
  • 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
  • Includes Updated List of tables & figures.
  • Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.

Key data covered in the market report

  • The report will help in developing business strategies by understanding trends shaping and driving the market.
  • To understand the future market competition in the market and an insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.

Some of the Top Market Players Are:

  • Bristol-Myers Squibb
  • Merck & Co.
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Amgen Inc.
  • Celgene Corporation
  • Johnson & Johnson

For Additional Information on Key Players, Download a PDF Brochure:   

Key factors driving market growth

  • Increasing the patient population to push the market

As per the American Cancer Society, the evaluated case of soft tissue sarcoma in 2023 is approximately 13,400 contemporary cases, with 7,400 in males and 6,000 in females. Further, it is evaluated that around about 5,000 people will expire due to soft tissue sarcoma in the same year. The soft tissue sarcoma treatment market size is expanding due to the increasing patient population, which eventually increases the demand for associated therapeutics, offering a backdrop for market growth.

The bulk of players in the market is targeting advanced new drugs and therapies to cure advanced cases. Soft tissue sarcoma treatment market sales are soaring as the market observes a robust pipeline from the key players and start-ups. This clinical research opens the way for superior treatment and establishes the foundation of basic growth.

Request for a Discount on this Report Before Purchase @

Recent trends influencing the market

New product launches and product compliance to drive the market

  • Prominent players are concentrating on intensifying their product portfolio through product instigations and contemporary product compliance for sarcoma treatment which is anticipated to boost market growth over the forecast period.
  • Players functioning in the market are concentrated on research and development of the contemporary and efficacious cure for sarcoma, which is anticipated to push the growth of the market over the forecast period.

Segmentation assessment

  • Anti-angiogenesis drugs segment is expected to witness the fastest growth over the forecast period

Based on treatment, the anti-angiogenesis drugs segment is expected to witness the fastest growth over the forecast period. Soft tissue sarcoma treatment market demand is increasing as there is an increasing demand for these drugs in cancer treatment. The segment is driven by the growing pervasiveness of cancer and the requirement for efficacious therapies. Anti-angiogenesis drugs utilize a molecular viewpoint to restrict the growth of contemporary blood vessels where the tumor needs to spread.

  • The metastatic sarcoma segment accounted for the largest market share

Based on indication, the metastatic sarcoma segment accounted for the largest market share. Soft tissue sarcoma treatment market trends include metastatic sarcoma, a kind of cancer that proliferates past its indigenous site of the body into varied organs or tissues. The cure for this type is cancer is rare, and the prediction is often poor. Thus the demand for effective treatment is high. Metastatic sarcoma is anticipated to be driven by the advancement of new drugs, such as immunotherapies and targeted therapies which have been effective in treating this kind of cancer.

Inquire more about this report before purchase @

(Inquire about a report quote OR available discount offers to the sales team before purchase.)

Soft Tissue Sarcoma Treatment Market: Report Scope

Report Attribute Details
Revenue forecast in 2032 USD 3,704.27 Million
Market size value in 2023 USD 1,482.59 Million
Expected CAGR Growth 10.7% from 2023 – 2032
Base Year 2022
Forecast Year 2023 – 2032
Top Market Players Bristol-Myers Squibb, Merck & Co., Eli Lilly and Company, Novartis AG, Pfizer Inc., GlaxoSmithKline plc, AstraZeneca plc, Amgen Inc., Celgene Corporation, Johnson & Johnson, Bayer AG, AbbVie Inc., Sanofi, Takeda Pharmaceuticals, and Gilead Sciences
Segments Covered By Payload, By Launch Platform, By Launch Vehicle, By End User, By Region
Customization Options Customized purchase options are available to meet any research needs. Explore customized purchase options

Geographic Overview

  • Obtainability of progressive treatments to propel the North American market

North America held the largest soft tissue sarcoma treatment market share due to the growing pervasiveness of this kind of cancer in the region and the obtainability of progressive treatments. Further, the growing concentration on research and development of inventive cures such as immunotherapies and targeted therapies is anticipated to drive the demand for the market in North America.

Browse the Detail Report “Soft Tissue Sarcoma Treatment Market Share, Size, Trends, Analysis, Industry Report By Treatment, By Disease, By Distribution Channel, By End User and Forecast, 2023 – 2032” with in-depth TOC:      

For Additional Information OR Media Enquiry, Please Mail At: [email protected]

Important Questions Answered by Report

  • What is the present size of the market?
  • What are the names of key players working in the market?
  • What are trending strategies utilized by market enterprises to expand their businesses?
  • What are the key regions of the market?
  • Which product type of the market is in high demand?
  • What is the projected size of the market at the end of the forecast period?

Polaris Market Research has segmented the Soft Tissue Sarcoma Treatment market report based on component, Treatment, Indication, Distribution Channel, end-use, and region:

By Treatment Outlook

  • Chemotherapy
  • Targeted Therapy
  • Anti-angiogenesis drugs
  • Radiation Therapy

By Indication Outlook

  • Regional
  • Local
  • Metastatic Sarcoma 

By Distribution Channel Outlook

  • Online Pharmacy 
  • Retail Pharmacy
  • Other

By End Use Outlook

  • Hospitals
  • Homecare
  • Others

By Region Outlook

  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Browse More Related Reports:

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.


Likhil G

30 Wall Street

8th Floor,

New York City, NY 10005,

United States

Phone: +1-929 297-9727

Email: [email protected]


Follow Us: LinkedIn Twitter


Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.